keyword
https://read.qxmd.com/read/38520556/pharmacology-and-pharmacokinetics-of-tazemetostat
#1
JOURNAL ARTICLE
Marco Orleni, Jan H Beumer
Tazemetostat, a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2), was approved by the Food and Drug Administration (FDA) in 2020 for use in patients with advanced epithelioid sarcoma or relapsed/refractory (R/R) EZH2-mutated follicular lymphoma. These indications were approved by the FDA trough accelerated approval based on objective response rate and duration of response that resulted from phase 2 clinical trials. Tazemetostat competes with S-adenosylmethionine (SAM) cofactor to inhibit EZH2, reducing the levels of trimethylated lysine 27 of histone 3 (H3K27me3), considered as pharmacodynamic marker...
March 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38517059/gamma-delta-t-cell-lymphoma-of-the-central-nervous-system-a-case-report-and-review-of-the-literature
#2
JOURNAL ARTICLE
Alexa T Andre, Meagan Chambers, Daniel E Sabath
Primary T-cell lymphoma (TCL) of the central nervous system (CNS) is a rare and potentially aggressive entity. We describe a case of TCL presenting in the basal ganglia with γδ receptor expression and a remarkably aggressive clinical course. To the best of our knowledge, this is the fifth reported case of γδ TCL presenting in the CNS. We review existing literature, including the previously reported cases of γδ TCL of the CNS. In our case, a 69-year-old male presented with acute onset dysarthria and right-sided weakness, with initial imaging concerning for stroke...
March 22, 2024: Clinical Neuropathology
https://read.qxmd.com/read/38516329/fully-automated-mr-based-virtual-biopsy-of-primary-cns-lymphomas
#3
JOURNAL ARTICLE
Vicky Parmar, Johannes Haubold, Luca Salhöfer, Mathias Meetschen, Karsten Wrede, Martin Glas, Maja Guberina, Tobias Blau, Denise Bos, Anisa Kureishi, René Hosch, Felix Nensa, Michael Forsting, Cornelius Deuschl, Lale Umutlu
BACKGROUND: Primary central nervous system lymphomas (PCNSL) pose a challenge as they may mimic gliomas on magnetic resonance imaging (MRI) imaging, compelling precise differentiation for appropriate treatment. This study focuses on developing an automated MRI-based workflow to distinguish between PCNSL and gliomas. METHODS: MRI examinations of 240 therapy-naive patients (141 males and 99 females, mean age: 55.16 years) with cerebral gliomas and PCNSLs (216 gliomas and 24 PCNSLs), each comprising a non-contrast T1-weighted, fluid-attenuated inversion recovery (FLAIR), and contrast-enhanced T1-weighted sequence were included in the study...
2024: Neuro-oncology advances
https://read.qxmd.com/read/38515768/primary-central-nervous-system-post-transplantation-lymphoproliferative-disorder-a-case-report-and-systematic-review-of-imaging-findings
#4
Dylan Hoyt, Jeremy Hughes, John Liu, Hashem Ayyad
Primary central nervous system post-transplant lymphoproliferative disease (PCNS-PTLD) is a rare subset of post-transplant lymphoproliferative disorder (PTLD) isolated to the CNS without nodal or extra-nodal organ involvement [1,2]. PCNS-PTLD occurs primarily in patients following either solid organ transplants or hematopoietic stem cell transplants and tends to be monomorphic DLBCL. The development of PCNS-PTLD is commonly associated with EBV infection [3]. Many intracranial pathologies can resemble the imaging appearance of PCNS-PTLD, including primary CNS lymphoma, glial tumors, metastatic disease, and intracranial abscesses...
June 2024: Radiology Case Reports
https://read.qxmd.com/read/38514025/fatal-outcome-of-bk-virus-encephalitis-in-an-allogeneic-stem-cell-transplantation-recipient
#5
Kyosuke Yamaguchi, Hisashi Yamamoto, Koji Izutsu, Mitsuhiro Yuasa, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Shuichi Taniguchi
BK virus (BKV) encephalitis is a rare complication after hematopoietic stem cell transplantation (HSCT). A 43-year-old woman with recurrent follicular lymphoma after autologous HSCT received allogeneic bone marrow transplantation from a human leukocyte antigen-matched related donor. Neutrophil engraftment was achieved on post-transplant day 13. Memory loss and noncooperative attitude toward the medical staff were observed on day 16, and her mental status worsened progressively. Magnetic resonance imaging (MRI) showed nonspecific findings on day 19; however, cerebrospinal fluid (CSF) analysis including real-time polymerase chain reaction on day 20 revealed elevated levels of BKV 4...
March 19, 2024: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://read.qxmd.com/read/38511272/systemic-diffuse-large-b-cell-lymphoma-involving-the-central-nervous-system-have-high-rates-of-defective-antigen-presentation-and-immune-surveillance
#6
JOURNAL ARTICLE
Joel Wight, Piers Blombery, Jennifer Lickiss, Melinda Burgess, Clare Gould, Adrian Minson, Fiona Swain, Muhammed B Sabdia, Maher K Gandhi, Andrew Birchley, Colm Keane, Eliza A Hawkes
Not available.
March 21, 2024: Haematologica
https://read.qxmd.com/read/38497149/efficacy-of-intravenous-high-dose-methotrexate-in-preventing-relapse-to-the-central-nervous-system-in-r-chop-like-treated-high-risk-diffuse-large-b-cell-lymphoma-patients-and-its-effect-on-mortality-a-systematic-review-and-meta-analysis
#7
JOURNAL ARTICLE
Elisabeth R Tolley, Christian Lewinter, Lars M Pedersen, Torsten Holm Nielsen
UNLABELLED: CNS relapse in patients with diffuse large B-cell lymphoma (DLBCL) carries a dismal prognosis with most clinical guidelines recommending CNS prophylaxis to patients deemed at high risk for CNS relapse. However, results from observational studies investigating the effect of CNS prophylaxis have yielded conflicting results. OBJECTIVES: To evaluate: 1) whether addition of prophylactic intravenous HD-MTX reduces the risk of CNS relapse in high-risk DLBCL patients treated with R-CHOP or similar and 2) whether HD-MTX prophylaxis confers an overall survival benefit, irrespective of CNS relapse...
March 14, 2024: Haematologica
https://read.qxmd.com/read/38496108/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-in-children-a-retrospective-cohort-study-at-a-pediatric-oncology-center
#8
JOURNAL ARTICLE
Leonardo Maia Moço, Ana Fraga, Iris Maia, Marta Almeida
Background and objective Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL Ph+) is quite rare among pediatric patients. Its management has undergone significant changes in the past few years, leading to some variability in how it is approached. At the Portuguese Oncology Institute of Porto (IPOP), a tertiary oncological center, the standard of care has been aligned with the guidelines proposed by the European intergroup study of post-induction treatment of ALL Ph+ (EsPhALL). In this study, we aimed to examine the experience and outcomes related to the treatment of pediatric patients with ALL Ph+ at IPOP...
February 2024: Curēus
https://read.qxmd.com/read/38494281/paraneoplastic-neuropathies-and-peripheral-nerve-hyperexcitability-disorders
#9
REVIEW
Shahar Shelly, Divyanshu Dubey, John R Mills, Christopher J Klein
Peripheral neuropathy is a common referral for patients to the neurologic clinics. Paraneoplastic neuropathies account for a small but high morbidity and mortality subgroup. Symptoms include weakness, sensory loss, sweating irregularity, blood pressure instability, severe constipation, and neuropathic pain. Neuropathy is the first presenting symptom of malignancy among many patients. The molecular and cellular oncogenic immune targets reside within cell bodies, axons, cytoplasms, or surface membranes of neural tissues...
2024: Handbook of Clinical Neurology
https://read.qxmd.com/read/38494076/bendamustine-as-lymphodepletion-for-brexucabtagene-autoleucel-therapy-of-mantle-cell-lymphoma
#10
JOURNAL ARTICLE
Elise A Chong, Emeline R Chong, Dylan Therwhangher, Sunita D Nasta, Daniel J Landsburg, Stefan K Barta, Jakub Svoboda, James N Gerson, Guido Ghilardi, Luca Paruzzo, Joseph A Fraietta, Elizabeth Weber, Natalie Stefano, David L Porter, Noelle V Frey, Alfred L Garfall, Marco Ruella, Stephen J Schuster
BACKGROUND: Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory mantle cell lymphoma (MCL). During a fludarabine shortage, we used bendamustine as an alternative to standard cyclophosphamide/fludarabine (cy/flu) lymphodepletion (LD) prior to brexu-cel. OBJECTIVES: We assessed MCL patient outcomes as well as CAR T-cell expansion and persistence after brexu-cel following bendamustine or cy/flu LD at our center...
March 15, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38494062/bifunctional-irgd-exo-dox-crosses-the-blood-brain-barrier-to-target-central-nervous-system-lymphoma
#11
JOURNAL ARTICLE
Tian Xia, Zhenyu Liu, Ying Du, Jiejie Zhang, Xu Liu, Jian Ouyang, Peipei Xu, Bing Chen
Central nervous system lymphoma (CNSL) is a type of hematological tumor. Treatment of CNSL is difficult due to the existence of the blood-brain barrier (BBB). Here, we used exosomes (Exos), a type of extracellular vesicle, and iRGD to construct a new drug carrier system and use it to load doxorubicin (DOX). The results of in vitro and in vivo experiments showed that the iRGD-Exo-DOX system can efficiently and securely transport DOX through the BBB and target tumor cells. The results suggest that iRGD-Exo-DOX may cross the BBB through brain microvascular endothelial cell-mediated endocytosis...
March 15, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38488146/covalent-fragment-screening-and-optimization-identifies-the-chloroacetohydrazide-scaffold-as-inhibitors-for-ubiquitin-c-terminal-hydrolase-l1
#12
JOURNAL ARTICLE
Ryan D Imhoff, Rishi Patel, Muhammad Hassan Safdar, Hannah B L Jones, Adan Pinto-Fernandez, Iolanda Vendrell, Hao Chen, Christine S Muli, Aaron D Krabill, Benedikt M Kessler, Michael K Wendt, Chittaranjan Das, Daniel P Flaherty
Dysregulation of the ubiquitin-proteasome systems is a hallmark of various disease states including neurodegenerative diseases and cancer. Ubiquitin C-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is expressed primarily in the central nervous system under normal physiological conditions, however, is considered an oncogene in various cancers, including melanoma, lung, breast, and lymphoma. Thus, UCHL1 inhibitors could serve as a viable treatment strategy against these aggressive cancers. Herein, we describe a covalent fragment screen that identified the chloroacetohydrazide scaffold as a covalent UCHL1 inhibitor...
March 15, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38484137/glofitamab-stimulates-immune-cell-infiltration-of-cns-tumors-and-induces-clinical-responses-in-secondary-cns-lymphoma
#13
JOURNAL ARTICLE
James K Godfrey, Lei Gao, Geoffrey Shouse, Joo Y Song, Stacy Pak, Brian Lee, Bihong T Chen, Avyakta Kallam, John H Baird, Guido Marcucci, Lucy Y Ghoda, Stephanie Vauleon, Alexey V Danilov, Alex F Herrera, Larry W Kwak, Lihua E Budde
Although CD20xCD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in CNS lymphoma is unknown. Here, we report the CD20xCD3 bispecific, glofitamab, penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces responses in CNS lymphoma.
March 14, 2024: Blood
https://read.qxmd.com/read/38482415/toripalimab-plus-lenalidomide-for-central-nervous-system-recurrence-in-refractory-cd5-diffuse-large-b-cell-lymphoma-with-myd88-and-cd79b-comutation-a-case-report
#14
Xi Chen, Zhihan Zhang, Junbao Zhang, Qiuxiao Yu, Junjing Qiu, Yajie Xiao, Binbin Chen, Ping Xu
BACKGROUND: CD5-positive (CD5+ ) non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) is heterogeneous with a poor prognosis. For refractory DLBCL, the median overall survival was only 6.3 months. Therefore, there is a need for approaches to elongate the survival in this subgroup of relapsed DLBCL patients. CASE DESCRIPTION: Here, we present a rare case of a 72-year-old patient with stage IV CD5+ non-GCB DLBCL with myeloid differentiation primary response 88 ( MYD88 ) and cluster of differentiation 79B ( CD79B ) comutations...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38476427/stereotactic-biopsy-for-brain-lesions-doing-more-with-less
#15
JOURNAL ARTICLE
Mayank Singh, T P Waseem Ahamed, Ved Prakash Maurya, Pragya Gupta, Kamlesh Singh Bhaisora, Arun Kumar Srivastava, Pawan Kumar Verma, Kuntal Kanti Das, Ashutosh Kumar, Priyadarshi Dikshit, Anant Mehrotra, Awadhesh Kumar Jaiswal, Sanjay Behari, Raj Kumar
OBJECTIVES: Stereotactic biopsy (STB) is a potential diagnostic tool considering its minimal invasiveness, high diagnostic yield, and minimal associated complications. Over the years, various frame-based instrument systems and frameless stereotactic biopsy systems have emerged to be employed in clinical use. With this study, we intend to get more by doing less in the form of STB for the patients of doubtful intracranial lesions treated over the past 5 years. We also want to highlight the technique of performing the procedure under scalp block, which can be used as a versatile tool in many clinical scenarios...
2024: Journal of Neurosciences in Rural Practice
https://read.qxmd.com/read/38473226/efficacy-and-safety-of-btkis-in-central-nervous-system-lymphoma-a-systematic-review-and-meta-analysis
#16
REVIEW
Yan Zhang, Jingjing Ye, Hao Chen, Daobin Zhou, Chunyan Ji
BACKGROUND: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKis) for central nervous system lymphoma (CNSL). METHODS: A systematic review was carried out to identify relevant studies from the PubMed, Embase, Cochrane Library, Web of Science, WanFang, CNKI, and CBM databases. The studies included patients with CNSL who received BTKis and reported the overall response (OR), complete remission (CR), and partial response (PR)...
February 21, 2024: Cancers
https://read.qxmd.com/read/38472552/neurolymphomatosis-as-primary-presentation-of-extra-nodal-nk-t-cell-lymphoma-nasal-type
#17
JOURNAL ARTICLE
Maria Inês Silva, Pedro Santos, Diana Viegas, Miguel Miranda, Vera Montes, Fernando Pita, Cátia Carmona
Neurolymphomatosis (NL) describes an infiltration of cranial and peripheral nerves by lymphoma cells, most frequently in non-Hodgkin B-cell lymphoma. This clinical entity is rare and poses a challenging diagnosis. We describe a case of a 64-year-old female patient with NL associated with extra-nodal NK/T-cell lymphoma (ENKTL), nasal type, presenting as a painful progressive mononeuropathy multiplex with an oral cavity lesion. ENKTL is usually associated with Epstein-Barr virus (EBV) infection and rarely affects the central and peripheral nervous system...
March 12, 2024: Neurological Sciences
https://read.qxmd.com/read/38466403/survival-outcomes-and-treatment-experience-of-124%C3%A2-patients-with-primary-central-nervous-system-lymphoma
#18
JOURNAL ARTICLE
Ziqing Tang, Geting Wu, Fang Tan, Yang Long, Jidong Hong, Zhiping Lyu, Rui Wei
PURPOSE: Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the central nervous system with high invasiveness. There is little consensus on the treatment of PCNSL. This study retrospectively studied data from PCNSL patients in a single center to summarize treatment experience and explore prognostic factors. METHODS: Survival curves were drawn using the Kaplan-Meier method and prognostic factors were analyzed using Cox's hazards model...
March 11, 2024: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://read.qxmd.com/read/38459978/executive-summary-of-the-american-radium-society-appropriate-use-criteria-for-brain-metastases-in-egfr-mutated-and-alk-fusion-non-small-cell-lung-cancer
#19
JOURNAL ARTICLE
Seema Nagpal, Michael T Milano, Veronica L Chiang, Scott G Soltys, Alexandria Brackett, Lia M Halasz, Amit K Garg, Arjun Sahgal, Manmeet S Ahluwalia, Martin C Tom, Joshua D Palmer, Jonathan P S Knisley, Samuel T Chao, Melanie Hayden Gephart, Tony J C Wang, Simon S Lo, Eric L Chang
BACKGROUND: The American Radium Society (ARS) Central Nervous System (CNS) committee reviewed literature on epidermal growth factor receptor mutated (EGFRm) and ALK-fusion (ALK+) tyrosine kinase inhibitors (TKIs) for the treatment of brain metastases (BrMs) from non-small cell lung cancers (NSCLC) to generate appropriate use guidelines addressing use of TKIs in conjunction with or in lieu of radiotherapy (RT). METHODS: The panel developed three key questions to guide systematic review: can radiotherapy be deferred in patients receiving EGFR or ALK TKIs at 1) diagnosis or 2) recurrence? Should TKI be administered concurrently with RT (3)? Two literature searches were performed (May 2019 and December 2023)...
March 9, 2024: Neuro-oncology
https://read.qxmd.com/read/38451075/stereotactic-radiotherapy-and-cart-for-treatment-of-secondary-cns-lymphoma
#20
JOURNAL ARTICLE
Wisdom Akingbemi, Goldie Kurtz, Nikhil Yegya-Raman, John P Plastaras, Stephen J Schuster, Elise A Chong
No abstract text is available yet for this article.
March 7, 2024: Leukemia & Lymphoma
keyword
keyword
171665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.